# Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL

> **NCT05552937** · PHASE2 · RECRUITING · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- DLBCL

## Interventions

- **DRUG:** Tafasitamab and Lenalidomide

## Key facts

- **NCT ID:** NCT05552937
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-06
- **Primary completion:** 2025-04
- **Final completion:** 2027-04
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05552937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05552937, "Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05552937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*